177 related articles for article (PubMed ID: 34593523)
1. Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.
Yang J; Gao C; Liu M; Liu YC; Kwon J; Qi J; Tian X; Stein A; Liu YV; Kong NR; Wu Y; Yin S; Xi J; Chen Z; Kumari K; Wong H; Luo H; Silberstein LE; Thoms JAI; Unnikrishnan A; Pimanda JE; Tenen DG; Chai L
Cancer Res; 2021 Dec; 81(23):6018-6028. PubMed ID: 34593523
[TBL] [Abstract][Full Text] [Related]
2. Targeting SALL4 by entinostat in lung cancer.
Yong KJ; Li A; Ou WB; Hong CK; Zhao W; Wang F; Tatetsu H; Yan B; Qi L; Fletcher JA; Yang H; Soo R; Tenen DG; Chai L
Oncotarget; 2016 Nov; 7(46):75425-75440. PubMed ID: 27705911
[TBL] [Abstract][Full Text] [Related]
3. Activation of Estrogen Receptor Alpha by Decitabine Inhibits Osteosarcoma Growth and Metastasis.
Lillo Osuna MA; Garcia-Lopez J; El Ayachi I; Fatima I; Khalid AB; Kumpati J; Slayden AV; Seagroves TN; Miranda-Carboni GA; Krum SA
Cancer Res; 2019 Mar; 79(6):1054-1068. PubMed ID: 30593524
[TBL] [Abstract][Full Text] [Related]
4. New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation.
Tan JL; Li F; Yeo JZ; Yong KJ; Bassal MA; Ng GH; Lee MY; Leong CY; Tan HK; Wu CS; Liu BH; Chan TH; Tan ZH; Chan YS; Wang S; Lim ZH; Toh TB; Hooi L; Low KN; Ma S; Kong NR; Stein AJ; Wu Y; Thangavelu MT; Suzuki A; Periyasamy G; Asara JM; Dan YY; Bonney GK; Chow EK; Lu GD; Ng HH; Kanagasundaram Y; Ng SB; Tam WL; Tenen DG; Chai L
Gastroenterology; 2019 Dec; 157(6):1615-1629.e17. PubMed ID: 31446059
[TBL] [Abstract][Full Text] [Related]
5. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex.
Gao C; Dimitrov T; Yong KJ; Tatetsu H; Jeong HW; Luo HR; Bradner JE; Tenen DG; Chai L
Blood; 2013 Feb; 121(8):1413-21. PubMed ID: 23287862
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.
Liu L; Liu L; Leung LH; Cooney AJ; Chen C; Rosengart TK; Ma Y; Yang J
J Biol Chem; 2015 Apr; 290(17):10599-609. PubMed ID: 25737450
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
8. S-adenosylmethionine in combination with decitabine shows enhanced anti-cancer effects in repressing breast cancer growth and metastasis.
Mahmood N; Arakelian A; Cheishvili D; Szyf M; Rabbani SA
J Cell Mol Med; 2020 Sep; 24(18):10322-10337. PubMed ID: 32720467
[TBL] [Abstract][Full Text] [Related]
9. Targeting SALL4 by Entinostat Inhibits the Malignant Phenotype of Gastric Cancer Cells by Reducing EMT Signaling.
DU L; Xie F; Han H; Zhang L
Anticancer Res; 2023 Oct; 43(10):4389-4401. PubMed ID: 37772555
[TBL] [Abstract][Full Text] [Related]
10. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma.
Yong KJ; Gao C; Lim JS; Yan B; Yang H; Dimitrov T; Kawasaki A; Ong CW; Wong KF; Lee S; Ravikumar S; Srivastava S; Tian X; Poon RT; Fan ST; Luk JM; Dan YY; Salto-Tellez M; Chai L; Tenen DG
N Engl J Med; 2013 Jun; 368(24):2266-76. PubMed ID: 23758232
[TBL] [Abstract][Full Text] [Related]
11. SALL4 promotes tumor progression in breast cancer by targeting EMT.
Chen T; Tsang JYS; Su XC; Li P; Sun WQ; Wong ILK; Choy KY; Yang Q; Tse GMK; Chan TH; Chow LMC
Mol Carcinog; 2020 Oct; 59(10):1209-1226. PubMed ID: 32835442
[TBL] [Abstract][Full Text] [Related]
12. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
13. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
[TBL] [Abstract][Full Text] [Related]
15. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
16. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
17. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
18. SALL4 induces radioresistance in nasopharyngeal carcinoma via the ATM/Chk2/p53 pathway.
Nie X; Guo E; Wu C; Liu D; Sun W; Zhang L; Long G; Mei Q; Wu K; Xiong H; Hu G
Cancer Med; 2019 Apr; 8(4):1779-1792. PubMed ID: 30907073
[TBL] [Abstract][Full Text] [Related]
19. Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.
Li K; Hu C; Mei C; Ren Z; Vera JC; Zhuang Z; Jin J; Tong H
J Transl Med; 2014 Jun; 12():167. PubMed ID: 24923330
[TBL] [Abstract][Full Text] [Related]
20. SALL4 is a key regulator of survival and apoptosis in human leukemic cells.
Yang J; Chai L; Gao C; Fowles TC; Alipio Z; Dang H; Xu D; Fink LM; Ward DC; Ma Y
Blood; 2008 Aug; 112(3):805-13. PubMed ID: 18487508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
